MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-20-3105

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2020

A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer.

Soliman Hatem, Hogue Deanna, Han Hyo, Mooney Blaise, Costa Ricardo, Lee Marie C, Niell Bethany, Williams Angela, Chau Alec, Falcon Shannon, Khakpour Nazanin, Weinfurtner Robert J, Hoover Susan, Kiluk John, Rosa Marilin, Khong Hung, Czerniecki Brian

Клиническое исследование I фазыСтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: Talimogene laherparepvec (TVEC) is an oncolytic herpes simplex 1 virus approved for treatment of melanoma. We hypothesized intratumoral TVEC may enhance response to neoadjuvant chemotherapy (NAC). This article reports the results of a trial combining NAC with TVEC for triple-negative breast cancer (TNBC).

PATIENTS AND

METHODS

Patients with stage II-III TNBC enrolled in a 3+3 phase I trial (NCT02779855) of two TVEC dose levels [DL; DL 1 = 106 plaque-forming units (PFU) × 5 doses; DL 2 = 106 PFUs first dose, then 108 PFUs × 4 doses] on weeks 1, 4, 6, 8, and 10 plus weekly paclitaxel (80 mg/m2) for 12 weeks, followed by doxorubicin/cyclophosphamide (60/600 mg/m2) every 2 weeks for 8 weeks. Postoperative response assessment using residual cancer burden (RCB) was performed. Primary endpoints were safety and MTD. Secondary endpoints were RCB0 rate and immune correlates. Dose-limiting toxicity (DLT) rule was grade 3-5 adverse events due to TVEC during first 5 weeks.

RESULTS

Nine patients [DL 1 (n = 3); DL 2 (n = 6)] were enrolled. Six had stage II disease, and 3 had stage III (6 clinically N+). No DLTs occurred, and MTD was DL 2. Most common toxicities with TVEC were fever (n = 8), chills (n = 3), hematomas (n = 3), and injection site pain (n = 3). Thromboembolic events (n = 2) and bradycardia (n = 1) occurred during or after NAC. Five patients (55%) achieved RCB0, 2 had RCB1 (22%), and 2 had RCB2 (22%).

CONCLUSIONS

The addition of TVEC to NAC was feasible at the approved dose, with manageable toxicity. The complete response rate was 55%.

Для цитирования: Soliman Hatem, Hogue Deanna, Han Hyo, Mooney Blaise, Costa Ricardo, Lee Marie C, Niell Bethany, Williams Angela, Chau Alec, Falcon Shannon, Khakpour Nazanin, Weinfurtner Robert J, Hoover Susan, Kiluk John, Rosa Marilin, Khong Hung, Czerniecki Brian. A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020. DOI: 10.1158/1078-0432.ccr-20-3105.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.